Melanoma | New England Journal of Medicine Skip to main content The New England Journal
of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology Clinical Medicine …

The idea that tumors must “escape” from immune recognition contains the implicit
assumption that tumors can be destroyed by immune responses either spontaneously or as …

The clinically important melanoma diagnostic antibodies HMB-45, melan-A, and MITF (D5)
recognize gene products of the melanocyte-lineage genes SILV/PMEL17/GP100 …

Optimal vaccine strategies must be identified for improving T‐cell vaccination against
infectious and malignant diseases. Mel Q b G 10 is a virus‐like nano‐particle loaded with A …

With the rapid growth of advanced nanoengineering strategies, there are great implications
for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial …

Tumor escape is one major obstacle that has to be addressed prior to designing and
delivering successful immunotherapy. There is compelling evidence to support the notion …

Determining the metastatic potential of intermediate thickness lesions remains a major
challenge in the management of melanoma. Clinical studies have demonstrated that …

Since the late 19th century, the immune system has increasingly garnered interest as a
novel avenue for cancer therapy, particularly given scientific breakthroughs in recent …

The protein kinase B-RAF is a human oncogene that is mutated in∼ 70% of human
melanomas and transforms mouse melanocytes. Microphthalmia-associated transcription …

Context.—The rapidly developing fields of melanoma research are revolutionizing the
current concepts on melanoma etiology and pathogenesis and are introducing newer …